文献速递临床试验与 GCP基础与转化研究

瘤内注射纳米复合poly I:C(BO-112)联合全身抗PD-1治疗抗PD-1难治性肿瘤的I期临床试验

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors.
PubMed 文献 · Sci Transl Med · 2020-01-01

这项多中心I期临床试验评估了瘤内注射BO-112(纳米复合poly I:C)单药及联合全身抗PD-1药物(纳武利尤单抗或帕博利珠单抗)在抗PD-1难治性肿瘤患者中的安全性和疗效。BO-112单药推荐剂量为1 mg可安全重复给药,联合治疗耐受良好,28例原发抗PD-1耐药患者中3例(2例黑色素瘤、1例肾细胞癌)达部分缓解,另有10例在8至12周时疾病稳定。提示局部BO-112联合全身抗PD-1可能逆转抗PD-1耐药。

要点

  • BO-112瘤内注射单药推荐剂量为1 mg,可安全重复给药。
  • 联合纳武利尤单抗或帕博利珠单抗耐受良好,28例抗PD-1耐药患者中3例部分缓解。
  • 局部BO-112联合全身抗PD-1可能成为逆转抗PD-1耐药的策略。

核心结论

  • 瘤内BO-112联合全身抗PD-1药物可能逆转抗PD-1耐药。

研究设计与样本

  • 多中心I期临床试验,BO-112瘤内重复给药,前三个队列为单药治疗,第四队列为联合纳武利尤单抗或帕博利珠单抗治疗28例原发抗PD-1耐药肿瘤患者。

主要发现

  • BO-112瘤内给药诱导肿瘤细胞坏死和凋亡增加,基因表达谱显示免疫反应性增强。
  • 单药前三个队列确定推荐剂量为1 mg可安全重复,报告2例3至4级可逆性血小板减少。
  • 联合治疗队列28例中3例(2例黑色素瘤、1例肾细胞癌)达部分缓解,另有10例在8至12周时疾病稳定。

关键数值与推荐

  • BO-112单药推荐剂量为1 mg,可安全重复给药。
  • 联合治疗队列中3例部分缓解,10例在8至12周时疾病稳定。

临床怎么用

  • 对于抗PD-1原发耐药肿瘤患者,可考虑瘤内注射BO-112联合全身抗PD-1治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intratumoral therapies, especially Toll-like receptor agonists, can trigger both the innate and adaptive immune systems. BO-112 is a nanoplexed form of polyinosinic:polycytidylic acid (poly I:C) that induces local and systemic immunotherapeutic effects in mouse models. In a multicenter phase 1 clinical trial, repeated intratumoral administrations of BO-112 induced an increase in tumor cell necrosis and apoptosis, as well as augmented immune reactivity according to gene expression profiling. The first three cohorts receiving BO-112 as a monotherapy resulted in a recommended dose of 1 mg that could be safely repeated. Two grade 3 to 4 adverse reactions in the form of reversible thrombocytopenia were reported. In a fourth cohort of 28 patients with tumors that had primary resistance to anti-programmed cell death protein-1 (PD-1), the combination of intratumoral BO-112 with nivolumab or pembrolizumab was also well tolerated, and 3 patients (2 with melanoma and 1 with renal cell carcinoma) achieved partial responses, with 10 more patients having stable disease at 8 to 12 weeks. Thus, local BO-112 combined with a systemic anti-PD-1 agent might be a strategy to revert anti-PD-1 resistance.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Márquez-Rodas I, Longo F, Rodriguez-Ruiz ME, et al. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors. Sci Transl Med. 2020. PMID: 33055241. doi:10.1126/scitranslmed.abb0391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。